PATENT CLAIM ANALYSIS

Application Number: 16112304
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "133100"]

Abstract:
The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.

Claim (Index 11):
The method of any one of  claims 3 - 6 , wherein the angiogenesis-related disease is an ocular disease characterized by angiogenesis/neovascularization, diabetic nephropathy, inflammatory bowel disease (IBD), rheumatoid arthritis, osteoarthritis, a cancer, or a metastasis.

Metadata:
- Claim Count in Document: 133.0
- Percentile: 96.0
- Lexical Diversity: 2.29167
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13485702', '14054446', '15337113', '14838006', '12751907']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7927660523515381
- 35 USC 102 Novelty (BERT): 0.554181973246181
- Combined Prediction Score: 0.7689076444410023
- Mean Citation Score: 385.918738
- Max Citation Score: 422.3443
- Similarity Product: 363.0364142997503

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test